OSR Holdings, Inc. Form 8-K Filing

OSR Holdings, Inc. (NASDAQ: OSRH) is making publicly available information regarding its drug development subsidiary, Vaximm AG, that was inadvertently referenced during a meeting with a sell-side research analyst on March 13, 2026. Vaximm is in negotiations with SillaJen, Inc. for a potential licensing agreement concerning Pexa-Vec, a drug for Renal Cell Carcinoma. Separately, OSR Holdings has had preliminary discussions about acquiring a controlling stake (approximately 16%) in SillaJen. Both matters are in early stages, subject to further negotiation, due diligence, and regulatory considerations, with no definitive agreements yet in place. This disclosure is made in accordance with Regulation FD to ensure broad public access to the information.